09th week of 2010 patent applcation highlights part 32 |
Patent application number | Title | Published |
20100056478 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors - A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI). | 2010-03-04 |
20100056479 | THE USE OF QUATERNARY AMMONIUM COMPOUNDS IN THE REMEDIATION OF MOLD, MILDEW, AND FUNGUSES - The present invention relates to the use of quaternary ammonium compounds in the remediation of microbial growth such as mold, funguses, and mildew. | 2010-03-04 |
20100056480 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS - The present invention relates to the use of an arginase inhibitor for the preparation of a medicament for the prophylactic maintenance therapy of an asthmatic or allergic patient by preventing obstruction of upper and lower airways, in particular allergen-induced bronchial obstruction and/or airway hyperresponsiveness. The patients are either asthmatic or have allergic rhinitis. Preferably, the arginase inhibitor is 2(S)-amino-6-boronohexanoic acid (ABH). | 2010-03-04 |
20100056481 | CRYSTALLINE FORMS OF ZOLEDRONIC ACID - The invention relates to new crystalline forms of low water soluble salts of zoledronic acid, the process for preparation of these crystalline forms, compositions containing these crystalline forms, and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the crystalline form of the free acid monohydrate of zoledronic acid, the process for preparation of the crystalline form of the free acid monohydrate of zoledronic acid, compositions containing the crystalline form of the free acid monohydrate of zoledronic acid, and the use of crystalline form of the free acid monohydrate of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. | 2010-03-04 |
20100056482 | Calixarene Derivatives as Anticancer Agent - This invention relates to compounds having the following formula (I): | 2010-03-04 |
20100056483 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF BONE LOSS - Disclosed herein are methods and compositions for the treatment and prevention of bone loss. The methods comprise providing a therapeutically effective amount of at least one chelating agent to a subject. The methods further comprise providing a therapeutically effective amount of estrogen or at least one estrogen analogue to a subject. Compositions disclosed herein for the treatment and prevention of bone loss comprise a chelator and estrogen or at least one estrogen analogue. The compositions further comprise at least one of a bisphosphonate, a selective estrogen receptor modulator, or a hormone. | 2010-03-04 |
20100056484 | DIETARY SUPPLEMENTAL COMPOSITION EFFECTIVE FOR ENHANCING COGNITIVE PERFORMANCE, ELEVATING MOOD AND REDUCING OXIDATIVE STRESS - A dietary supplemental composition composed of Acetyl-L-Carnitine, Phosphatidylserine, L-Alpha-Glycerylphosphorylcholine, fish oils including Docosahexaenoic acid, Alpha Lipoic Acid, and optionally Eicosapentaenoic acid, and which in combination has been demonstrated to be effective in increasing cognitive performance, elevating mood and decreasing oxidative stress levels in mammals. | 2010-03-04 |
20100056485 | NANOSOAP CONTAINING SILVER NANOPARTICLES - Disclosed herein is a silver nanoparticle based antimicrobial composition and methods for making the same. The antimicrobial composition comprises an amphiphilic molecule having at least one hydrophilic group and at least hydrophobic groups attached thereto; and an at least one silver nanoparticle in contact with the amphiphilic molecule. Also disclosed are uses for the antimicrobial composition such as for the treatment of skin disorders. | 2010-03-04 |
20100056486 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2010-03-04 |
20100056487 | MODULATORS OF AMYLOID-BETA PRODUCTION - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 2010-03-04 |
20100056498 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS - Compounds of formula I: | 2010-03-04 |
20100056499 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF - The present invention provides compounds of the formula: | 2010-03-04 |
20100056500 | Stable Parenteral Formulation - The present invention relates to pharmaceutical formulations of benzodiazepine compounds which are active against Respiratory Syncytial Virus (RSV) suitable for parenteral administration. | 2010-03-04 |
20100056501 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION - This invention relates to novel lactams of Formula (I): | 2010-03-04 |
20100056502 | COMPOUNDS - Tricyclic nitrogen containing compounds and their use as antibacterials. | 2010-03-04 |
20100056503 | Compounds for modulating integrin CD11b/CD18 - The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | 2010-03-04 |
20100056504 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS - The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. | 2010-03-04 |
20100056505 | Substituted Pyrazalones - The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable. | 2010-03-04 |
20100056506 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS - The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R | 2010-03-04 |
20100056507 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT - The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said new phenylic derivatives and to methods for the preparation and use thereof. | 2010-03-04 |
20100056528 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS - The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents. | 2010-03-04 |
20100056529 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES - This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA-A receptor antagonist and/or a α2, α3 and α5 GABA-A receptor agonist. | 2010-03-04 |
20100056530 | GLUCOKINASE ACTIVATORS - Provided are compounds of Formula I wherein R | 2010-03-04 |
20100056531 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5-HT | 2010-03-04 |
20100056532 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2010-03-04 |
20100056533 | 18F-LABELLED FOLATES - The present invention is directed towards new | 2010-03-04 |
20100056534 | PESTICIDAL COMPOSITIONS - Pesticide compositions and their use in controlling pests are provided. | 2010-03-04 |
20100056535 | Inhibitors of HIV-1 reverse transcriptase - The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to Formulae I and II | 2010-03-04 |
20100056536 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 2010-03-04 |
20100056537 | PHARMACEUTICAL COMPOSITION HAVING RELATIVELY LOW IONIC STRENGTH - The present invention is directed to the provision of pharmaceutical compositions such as multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy preservative efficacy requirements in the United States and/or Europe. The compositions include sorbate or a non-polymeric diquaternary ammonium compound for enhancing preservation efficacy. Further, the compositions typically have relatively low ionic strengths to assist in maintaining such efficacy. | 2010-03-04 |
20100056538 | Pro-drugs of A2B Adenosine Receptor Antagonists - Disclosed are prodrugs of A | 2010-03-04 |
20100056539 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2010-03-04 |
20100056540 | STABLE PHARMACEUTICAL COMPOSITION FOR OPTIMIZED DELIVERY OF AN HIV ATTACHMENT INHIBITOR - A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors. | 2010-03-04 |
20100056541 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2010-03-04 |
20100056542 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid | 2010-03-04 |
20100056543 | POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF - Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons. | 2010-03-04 |
20100056544 | Salts with CRTH2 Antagonist Activity - The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R | 2010-03-04 |
20100056545 | NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT - Disclosed herein are a new phenylacetate derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for prevention or treatment of diseases induced by the activation of T-type calcium ion channels containing the same. The composition containing the phenylacetate derivative according to the present invention effectively inhibits the activation of T-type calcium ion channels and may be useful in the prevention or treatment of diseases such as hypertension, cancer, epilepsy, and neurogenic pains induced by the activation of T-type calcium ion channels. | 2010-03-04 |
20100056546 | SULFONYLUREA INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof. | 2010-03-04 |
20100056547 | OPHTHALMIC COMPOSITIONS COMPRISING dDC - A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein. | 2010-03-04 |
20100056568 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives - The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) | 2010-03-04 |
20100056569 | Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents - The invention relates a kind of antiviral agents, more concretely, relates to a kind of heterocyclic non-nucleoside compounds with the following structures, their preparation and pharmaceutical compositions including the compounds. The said compounds can be used as antiviral agents and as medicaments for treating diseases such as hepatitis B, influenza, herpes, HIV and so on. | 2010-03-04 |
20100056570 | FUNGICIDES - Compounds of the general formula wherein the substituents are as defined in claim ( | 2010-03-04 |
20100056571 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS - Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- | 2010-03-04 |
20100056572 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE - Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications. | 2010-03-04 |
20100056573 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS - 2-Alkyl-indazole compound and its pharmaceutically acceptable salts of acid addition, method and intermediates for preparing them, a pharmaceutical composition containing them and use of the latter. The 2-alkyl-indazole compound has the following general formula (I) in which R1, R2, R3, R4, R6, R7, X, Y, W, n, p, and m have the meanings stated in the description. | 2010-03-04 |
20100056574 | Crystalline Forms of Sufentanil - The present invention provides crystalline forms of sufentanil citrate and methods for preparing crystalline forms of sufentanil citrate. | 2010-03-04 |
20100056575 | Anesthetic Compounds - In one embodiment the invention provides novel compounds of Formula (I) as well as prodrugs, salts, hydrates, solvates and N-oxides thereof. The invention also provides pharmaceutical compositions that include such compounds as well as methods for making and methods for using such compounds in medical therapy. | 2010-03-04 |
20100056576 | Kinase inhibitors and methods of their use - New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer. | 2010-03-04 |
20100056577 | PYRROLE COMPOUNDS - The present invention relates to a compound represented by the formula: | 2010-03-04 |
20100056578 | INSECTICIDAL N-SUBSTITUTED SULFOXIMINES - N-Substituted sulfoximines are effective at controlling insects. | 2010-03-04 |
20100056579 | INSECTICIDAL N-SUBSTITUTED SULFOXIMINES - N-Substituted sulfoximines are effective at controlling insects. | 2010-03-04 |
20100056580 | NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND - A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for making pharmaceutical formulations for the treatment of type 2 diabetes, hyperglycemia, obesity, and dyslipidemia. | 2010-03-04 |
20100056581 | Substituted Piperidino Phenyloxazolidinones - The present invention relates to certain substituted piperidino phenyloxazolidinones. Specifically, the invention relates to geminally disubstituted piperidino phenyloxazolidinones having antimicrobial activity with improved pharmacokinetic profile. The invention also relates to processes for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating or preventing microbial infections using the compounds of the present invention. | 2010-03-04 |
20100056582 | Modulators of LXR - Compounds of the invention, such as compounds of formula (I): | 2010-03-04 |
20100056583 | Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation - The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms. | 2010-03-04 |
20100056584 | NOVEL 2-AMINIO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel 2-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2010-03-04 |
20100056585 | N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzam- ide (MS-275) Polymorph B - The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I | 2010-03-04 |
20100056586 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH - Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5′-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria. | 2010-03-04 |
20100056587 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use - Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders. | 2010-03-04 |
20100056588 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 2010-03-04 |
20100056589 | PLANT DISEASE DAMAGE CONTROL COMPOSITION AND PLANT DISEASE DAMAGE PREVENTION AND CONTROL METHOD - The invention provides a plant disease control composition including active ingredients of (RS)—N-[2-(1,3-dimethylbutyl)thiophene-3-yl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (common name: penthiopyrad) and at least one fungicidal compound other than penthiopyrad, and a plant disease prevention method wherein such a compound is applied to plant seeds or soil. According to the invention, a composition and a prevention method are provided which demonstrate a prevention effect against plural types of disease pathogenic microbes, and also demonstrate a preventing effect to currently emerging resistant pathogenic microbes, when applied to plant seed or soil. | 2010-03-04 |
20100056590 | POLYMORPHIC FORMS OF DEFERASIROX (ICL670A) - The invention relates to crystalline forms of -[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body. | 2010-03-04 |
20100056591 | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators - Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed. | 2010-03-04 |
20100056592 | PRODRUGS OF (3,5-BIS(4-FLUOROPHENYL)TETRAHYDRO-1H-OXAZOLO[3,4-C]OXAZOL-7A-YL)METHANOL AND DERIVATIVES THEREOF - A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof, or salts thereof, wherein: A and B are sulfur or oxygen; R1 and R2, in para, meta, or ortho position, are independently halogen, alkyl, alkoxy, haloalkyl, where R1 and R2 independently are straight chain, branched, substituted or unsubstituted; and R3 is a prodrug moiety. As examples, the prodrug can have a structure of any of Formulas I-V, which as shown in the specification. | 2010-03-04 |
20100056593 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2010-03-04 |
20100056594 | PLANT DISEASE AND INSECT DAMAGE CONTROL COMPOSITION, AND PLANT DISEASE AND INSECT DAMAGE PREVENTION METHOD - A composition including active ingredients of penthiopyrad and at least one neonicotinoid compound chosen from the group consisting of dinotefuran, clothianidin, nitenpyram, thiamethoxam, imidacloprid, thiacloprid, and acetamiprid, and a plant disease and insect damage prevention method of applying such a composition to a plant seed, are provided. According to the invention, a composition and a prevention method are provided which demonstrate a high degree of prevention effect and residual effectiveness against plural types of disease and insect damage, and also demonstrate a stable preventing effect to currently emerging resistant pathogens and resistant pest insects. | 2010-03-04 |
20100056595 | Pyrazole Derivatives as P2X7 Modulators - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2010-03-04 |
20100056596 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS - Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided. | 2010-03-04 |
20100056597 | INDOLEDIONE DERIVATIVE - A compound represented by the general formula (I-a): | 2010-03-04 |
20100056598 | CIS-ALKOXY-SUBSTITUTED SPIROCYCLIC 1H-PYRROLIDINE-2,4-DIONE DERIVATIVES SERVING AS PESTICIDES - The invention relates to a plurality of processes for the preparation of novel cis-alkoxy-substituted spirocyclic 1H-pyrrolidine-2,4-dione derivatives of the formula (I) | 2010-03-04 |
20100056599 | SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS - Synthesis of novel substituted indeno[1,2-b]indole derivatives of the type of 5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-diones and 5H-indeno[1,2-b]indole-6,9,10-triones, which show pronounced inhibition of the human protein kinase CK2, and the use thereof as active ingredients in medicaments and/or drug products in particular for the treatment of neoplastic diseases. | 2010-03-04 |
20100056600 | 11BETA-HSD1 ACTIVE COMPOUNDS - A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. | 2010-03-04 |
20100056601 | Control agent containing N-Substituted indole derivative for acarian parasitic on animal - Conventional control agents against acarians parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal activity of N-substituted indole compounds against acarians and on the safety thereof for mammals including pets. As a result, it was found that an N-substituted indole derivative, e.g., 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(trifluoromethylthio)indole, or 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(dichlorofluoromethylthio)indole, has high insecticidal activity and quick-acting properties and is lowly toxic to mammals including pets. | 2010-03-04 |
20100056602 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 2010-03-04 |
20100056603 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 2010-03-04 |
20100056604 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY INHIBITING PHOSPHODIESTERASE TYPE IV - The invention relates to the novel identification of inhibitors of phosphodiesterase type 4 (“PDE4”) as agents which can reverse inhibition of neural regeneration in the mammalian central and peripheral nervous system. The invention provides compositions and methods using agents that can reverse the inhibitory effects on neural regeneration by regulating PDE4 expression. A composition comprising at least one PDE4 inhibitor in an amount effective to inhibit PDE4 activity in a neuron when administered to an animal is provided. Methods for regulating (e.g., promoting) neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering to an animal a composition comprising a therapeutically effective amount of an agent which inhibits phosphodiesterase IV activity in a neuron are provided. | 2010-03-04 |
20100056605 | OXIDATIVE DEGRADATION PRODUCTS OF ATORVASTATIN CALCIUM - The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium. | 2010-03-04 |
20100056606 | Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha - Provided herein is a method for reducing the amount of steroid required for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness, comprising administration of the steroid and an oligonucleotide targeted to IL-4R alpha. Also described is a method for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness comprising administration of a corticosteroid and an oligonucleotide targeted to IL-4R alpha. Further provided are compositions comprising a corticosteroid and an IL-4R alpha targeted antisense oligonucleotide. | 2010-03-04 |
20100056607 | COMPOSITIONS AND THEIR USES DIRECTED TO HBXIP - Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. | 2010-03-04 |
20100056628 | Preservative compositions - Green and naturally derived biocides such as N | 2010-03-04 |
20100056629 | RETROVIRUS-INFECTION INHIBITOR - An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof. | 2010-03-04 |
20100056630 | COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF FIRE BLIGHT - The invention relates to an agent for treating and/or preventing fire blight, particularly present in wood and fruit trees, comprising formic acid and/or a salt of formic acid, particularly calcium formiate as an active component. Further disclosed is the use of formic acid and/or a salt of formic acid, particularly calcium formiate as an active component in herbicides, particularly for treating and/or preventing fire blight, and the use of formic acid and/or a salt of formic acid, particularly calcium formiate, for the production of an agent for treating and/or preventing fire blight. | 2010-03-04 |
20100056631 | ANTIALLERGENIC COMPOSITION - An antiallergenic composition comprising 3-hydroxybutyric acid and/or a salt thereof. The antiallergenic composition is safe. | 2010-03-04 |
20100056632 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 2010-03-04 |
20100056633 | SOLID OR AQUEOUS ALKALINE PREPARATION COMPRISING A CREATINE COMPONENT, PROCESS FOR THE PRODUCTION THEREOF AND THE USE THEREOF - A solid or aqueous alkaline preparation comprising a creatine component which comprises a buffer system which adjusts a pH of from 8.0 to 12.0 is described. The creatine is better protected with the aid of the buffer system from conversion into creatinine in the stomach. It has additionally emerged, surprisingly, that the novel formulations display a distinctly higher bioavailability and are thus taken up better by cells. Finally, the preparation of the invention has very good organoleptic properties, which in fact likewise could not be predicted. Owing to these particular advantages, the preparation of the invention is outstandingly suitable as dietary supplements, restoratives, medicinal products and feedstuffs. | 2010-03-04 |
20100056634 | NOVEL COMPOSITIONS - The present invention relates to novel composition for the treatment, co-treatment or prevention of inflammatory disorders comprising an effective amount of carnosic acid 12-methylether. | 2010-03-04 |
20100056635 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF - The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer. | 2010-03-04 |
20100056636 | N-Substituted-P-Menthane-3-Carboxamide and Uses Thereof - The present invention relates to substances and compositions having a physiological cooling effect on the skin and the mucosa of the body, especially of the oral cavity, throat and nose. More in particular, the present invention relates to N-substituted-p-menthane-3-carboxamides represented by the following formula (I): | 2010-03-04 |
20100056637 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS - The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease. | 2010-03-04 |
20100056668 | Opacifying pigment particle - An opacifying pigment encapsulated in polymer including a pigment particle having an average particle diameter of from 0.005 to 5 microns and an index of refraction of at least 1.8; an aminophosphorus acid-functional first polymer having been used to disperse the pigment particle in an aqueous medium; and a second polymer that at least partially encapsulates the dispersed pigment particle is provided. A process for forming the opacifying pigment encapsulated in polymer and compositions including the particles are also provided. | 2010-03-04 |
20100056669 | RUBBERIZED ASPHALT PELLETS - A storage-stable rubberized asphalt paving pellet can include fines in the core. The core can be an asphalt-based binder at about 70% to about 95% by weight of the core. The asphalt-based binder can include: ground tire rubber from about 15% to about 30% by weight of the asphalt-based binder, and pavement grade asphalt from about 85% to about 70% by weight of the asphalt based binder. The core can include fines at about 30% to about 1% by weight of the core. The shell coating the core can provide the pellet with a maximum dimension of about 1/16 inch to about 2 inches. The shell can include a water-resistant polymer or wax, or a coating of fines. In one aspect, the fines are lime fines or ground asphalt pavement fines. Optionally, the fines can be mineral or rock fines as described herein. | 2010-03-04 |
20100056670 | TIRE COMPOUNDS WITH IMPROVED TEAR, FLEX FATIGUE, AND OZONE RESISTANCE - A method of producing a tire including mixing in a non-productive phase at least one elastomer with a polyamide having a melting temperature of less than 180° C. The polyamide is allowed to heat to at least its melting temperature. During the productive phase, at least one curing agent is added to the elastomeric composition. The curing agent may be a sulfur containing curing agent and/or a non-sulfur containing curing agent. The elastomeric composition may optionally include a crystalline EPDM elastomer. The resulting compositions may then be formed into a tire component which may be built into a tire and cured. | 2010-03-04 |
20100056671 | POLYFUNCTIONAL EPOXY OLIGOMERS - The present invention provides epoxy functional oligomeric compounds, methods of preparation and uses therefor. In particular, the present invention provides to oligomeric epoxy compounds derived from allyl glycidyl ether. | 2010-03-04 |
20100056672 | BIODEGRADABLE BLENDS BASED ON HYDROLYSED PROTEINS AND FUNTIONALISED ETHYLENE COPOLYMERS - This invention relates to a new class of blend containing segments with a peptide base of hydrolysed proteins and gelatin, and segments with a polymer base consisting of variously substituted polyethylenes such as EVA and EVAL, and a method for their preparation. | 2010-03-04 |
20100056673 | Polyoxymethylene Compositions and Articles Made From These - Polyoxymethylene compositions that include 90 to 99.9 weight percent of at least one polyacetal polymer and 0.1 to 10 wt % of at least one polysaccharide substantially free of acidic material selected from the group consisting of amylopectin from maize and soluble starch where the weight percent of the polymer and the polysaccharide are based on their combined weight. Articles made from these compositions. | 2010-03-04 |
20100056674 | MODIFIED ASPHALT AND TWO-COMPONENT RESIN COMPOSITION - Modified asphalts have excellent dispersibility and compatibility with polar materials, are usable in applications including railroad track-filling materials, and are inexpensive. | 2010-03-04 |
20100056675 | STABILIZER FOR POLYOLEFIN RESIN AND STABILIZED POLYOLEFIN RESIN COMPOSITION - Disclosed is a stabilizer capable of giving a high degree of thermal stability to a polypropylene resin (PP resin). Also disclosed is a PP resin composition to which the stabilizer is added having a high degree of stability. Specifically disclosed is a stabilizer containing a copolymer (A) which is obtained by polymerizing an unsaturated monomer mixture composed of 1 to 50 parts by mass of an ethylenically unsaturated monomer (a) represented by the following general formula (I) and having a piperidyl group in a molecule, 50 to 99 parts by mass of at least one monomer (b) selected from isobutyl methacrylate, an alkyl (meth)acrylate having an alkyl group with 6 to 13 carbon atoms, and an aromatic vinyl monomer, and 0 to 20 parts by mass of an ethylenically unsaturated monomer (c) other than the monomers (a) and (b), with the proviso that the total of the monomers (a), (b), and (c) is 100 parts by mass: | 2010-03-04 |
20100056676 | POLYACETAL RESIN COMPOSITION AND MOLDED ARTICLE THEREOF - The present invention provides a polyacetal resin composition having excellent processability and stability, significantly suppressing the amount of formaldehyde generated from the molded article thereof, and preventing the bleeding of blending components. Specifically, to 100 parts by weight of (A) a polyacetal copolymer having 1.0 mmol/kg or less of hemiformal terminal group, 0.5 mmol/kg or less of formyl terminal group, and 0.5% by weight or less of unstable terminal group, there are blended: 0.01 to 3 parts by weight of (B) a hindered phenol-based antioxidant; 0.05 to 1 part by weight of (C) at least one compound selected from a guanamine compound and a triazine compound; and 0.01 to 1 part by weight of (D) a compound selected from an isocyanate compound, an isothiocyanate compound, and a modified compound thereof. | 2010-03-04 |
20100056677 | TOUGHENED HALOGEN FREE FLAME RETARDANT POLYESTER COMPOSITION - The invention relates to halogen free flame retardant thermoplastic polymer composition comprising a halogen free flame retardant system, a thermoplastic polyester and an amount of 1-20 wt. % of soft blocks chemically bonded to the thermoplastic polyester. The invention also relates to the use of the halogen free flame retardant thermoplastic polymer composition for making fibres, films and injection or extrusion moulded parts. | 2010-03-04 |